Frontline therapy with R-CHOP for diffuse large B-cell lymphoma: Where have we come (or not come)? A Perspective

被引:8
作者
Morrison, Vicki A. [1 ]
机构
[1] Univ Minnesota, Hennepin Cty Med Ctr, Dept Med, Hematol Oncol, 715 8th St, Minneapolis, MN 55404 USA
关键词
Non-Hodgkin lymphoma; Diffuse large B-cell lymphoma; Chemotherapy; Chemoimmunotherapy; Clinical trials; RITUXIMAB PLUS CYCLOPHOSPHAMIDE; PHASE-III TRIAL; METABOLIC TUMOR VOLUME; ELDERLY-PATIENTS; OPEN-LABEL; INTENSIFIED CHEMOTHERAPY; MAINTENANCE RITUXIMAB; YOUNG-PATIENTS; OLDER PATIENTS; SINGLE-ARM;
D O I
10.1016/j.jgo.2020.09.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A major evolution in the treatment of patients with diffuse large B-cell lymphoma (DLBCL) occurred almost two decades ago, with clinical trials demonstrating that the addition of rituximab (R) to cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP), which had been the "gold standard" of therapy since 1976, significantly improved outcome, including response rate and disease-free survival, of these patients. Since the adoption of R-CHOP, subsequent clinical trials have attempted to improve upon outcomes achieved with R-CHOP, with a variety of approaches examined. These have included dose intensification, which may be applicable in younger patients, but not in the many older or frailer patients with a disease with median age at diagnosis in the 60's. Newer anti-CD20 monoclonal antibodies have been substituted for rituximab in frontline regimens. A series of new agents, with unique mechanisms of action, have been added to the R-CHOP backbone. Rituximab-based, nonanthracycline regimens have been studied for older, more frail patients. The utility of maintenance therapy in responding patients has been re-examined, despite the lack of benefit found in the US Intergroup trial. Advances in molecular and genetic aspects of DLBCL have emerged since the seminal R-CHOP trials, demonstrating the DLBCL is not a single entity, but instead a spectrum of multiple disease subtypes. Attempts have been made to identify those patients at baseline who have poorer outcomes with standard approaches, utilizing laboratory and imaging findings. Moving forward, different risk-adapted treatment approaches will be studied to in an effort to improve overall outcome beyond R-CHOP. (c) 2020 Elsevier Ltd. All rights reserved.
引用
收藏
页码:320 / 325
页数:6
相关论文
共 51 条
[1]   Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303 [J].
Bartlett, Nancy L. ;
Wilson, Wyndham H. ;
Jung, Sin-Ho ;
Hsi, Eric D. ;
Maurer, Matthew J. ;
Pederson, Levi D. ;
Polley, Mei-Yin C. ;
Pitcher, Brandelyn N. ;
Cheson, Bruce D. ;
Kahl, Brad S. ;
Friedberg, Jonathan W. ;
Staudt, Louis M. ;
Wagner-Johnston, Nina D. ;
Blum, Kristie A. ;
Abramson, Jeremy S. ;
Reddy, Nishitha M. ;
Winter, Jane N. ;
Chang, Julie E. ;
Gopal, Ajay K. ;
Chadburn, Amy ;
Mathew, Susan ;
Fisher, Richard I. ;
Richards, Kristy L. ;
Schoder, Heiko ;
Zelenetz, Andrew D. ;
Leonard, John P. .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (21) :1790-+
[2]   SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model [J].
Ceriani, Luca ;
Gritti, Giuseppe ;
Cascione, Luciano ;
Pirosa, Maria Cristina ;
Polino, Angela ;
Ruberto, Teresa ;
Stathis, Anastasios ;
Bruno, Andrea ;
Moccia, Alden A. ;
Giovanella, Luca ;
Hayoz, Stefanie ;
Schaer, Saemi ;
Dirnhofer, Stefan ;
Rambaldi, Alessandro ;
Martinelli, Giovanni ;
Mamot, Christoph ;
Zucca, Emanuele .
BLOOD ADVANCES, 2020, 4 (06) :1082-1092
[3]   Diffuse large B-cell lymphoma: R-CHOP failure-what to do? [J].
Coiffier, Bertrand ;
Sarkozy, Clementine .
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, :366-378
[4]   Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma [J].
Crump, Michael ;
Leppa, Sirpa ;
Fayad, Luis ;
Lee, Je Jung ;
Di Rocco, Alice ;
Ogura, Michinori ;
Hagberg, Hans ;
Schnell, Frederick ;
Rifkin, Robert ;
Mackensen, Andreas ;
Offner, Fritz ;
Pinter-Brown, Lauren ;
Smith, Sonali ;
Tobinai, Kensei ;
Yeh, Su-Peng ;
Hsi, Eric D. ;
Tuan Nguyen ;
Shi, Peipei ;
Hahka-Kemppinen, Marjo ;
Thornton, Don ;
Lin, Boris ;
Kahl, Brad ;
Schmitz, Norbert ;
Savage, Kerry J. ;
Habermann, Thomas .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (21) :2484-+
[5]   Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles [J].
Cunningham, David ;
Hawkes, Eliza A. ;
Jack, Andrew ;
Qian, Wendi ;
Smith, Paul ;
Mouncey, Paul ;
Pocock, Christopher ;
Ardeshna, Kirit M. ;
Radford, John A. ;
McMillan, Andrew ;
Davies, John ;
Turner, Deborah ;
Kruger, Anton ;
Johnson, Peter ;
Gambell, Joanna ;
Linch, David .
LANCET, 2013, 381 (9880) :1817-1826
[6]   Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial [J].
Delarue, Richard ;
Tilly, Herve ;
Mounier, Nicolas ;
Petrella, Tony ;
Salles, Gilles ;
Thieblemont, Catherine ;
Bologna, Serge ;
Ghesquieres, Herve ;
Hacini, Maya ;
Fruchart, Christophe ;
Ysebaert, Loic ;
Ferme, Christophe ;
Casasnovas, Olivier ;
Van Hoof, Achiel ;
Thyss, Antoine ;
Delmer, Alain ;
Fitoussi, Olivier ;
Molina, Thierry Jo ;
Haioun, Corinne ;
Bosly, Andre .
LANCET ONCOLOGY, 2013, 14 (06) :525-533
[7]   Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma [J].
Gang, Anne O. ;
Pedersen, Mette O. ;
Knudsen, Helle ;
Lauritzen, Anne F. ;
Pedersen, Michael ;
Nielsen, Signe L. ;
Brown, Peter ;
Hogdall, Estrid ;
Klausen, Tobias W. ;
Norgaard, Peter .
LEUKEMIA & LYMPHOMA, 2015, 56 (07) :2039-2046
[8]   Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma [J].
Habermann, Thomas M. ;
Weller, Edie A. ;
Morrison, Vicki A. ;
Gascoyne, Randy D. ;
Cassileth, Peter A. ;
Cohn, Jeffrey B. ;
Dakhil, Shaker R. ;
Woda, Bruce ;
Fisher, Richard I. ;
Peterson, Bruce A. ;
Horning, Sandra J. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) :3121-3127
[9]   A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma [J].
Hainsworth, John D. ;
Arrowsmith, Edward R. ;
McCleod, Michael ;
Hsi, Eric D. ;
Hamid, Oday ;
Shi, Peipei ;
Lin, Boris K. ;
Fayad, Luis E. .
LEUKEMIA & LYMPHOMA, 2016, 57 (01) :216-218
[10]   Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray [J].
Hans, CP ;
Weisenburger, DD ;
Greiner, TC ;
Gascoyne, RD ;
Delabie, J ;
Ott, G ;
Müller-Hermelink, HK ;
Campo, E ;
Braziel, RM ;
Jaffe, ES ;
Pan, ZG ;
Farinha, P ;
Smith, LM ;
Falini, B ;
Banham, AH ;
Rosenwald, A ;
Staudt, LM ;
Connors, JM ;
Armitage, JO ;
Chan, WC .
BLOOD, 2004, 103 (01) :275-282